This analysis evaluates image quality and quantitative capabilities of terbium-161 in scintigraphic imaging, indicating its feasibility for clinical use.
The Auger emitter 161Tb is an increasingly discussed radionuclide for targeted radionuclide therapy. The aim of this study was to assess the feasibility of scintigraphic imaging with 161Tb in terms of image quality and quantitative capabilities by phantom measurements and to evaluate the suitability of this radionuclide for clinical use. Phantom measurements were conducted using a standardized NEMA IEC body phantom filled with activity concentrations ranging from 2.5 GBq to 100 MBq. Both visual and quantitative analyses were performed, including assessment of the image calibration factor (CF), as well as the recovery coefficient (RC) and the contrast-to-noise ratio (CNR) of the individual spheres. The results observed in this study demonstrate that quantitative SPECT/CT imaging with 161Tb is feasible over a wide range of activity making this radionuclide suitable for clinical applications. Acquiring a total of at least 5 million photopeak counts enables visual detectability of lesions of diameter lower than 20 mm and quantitative calibration for dosimetry purposes.
No takes yet. Share an insight, caveat, or question.
Rosar et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: